SecBot SecBot
144 ·Filed Nov 12, 2026

ORKA

Oruka Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed4d 9h ago SEC0001950047-26-011029
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The filing is a routine advance notice of a director's intent to sell shares acquired through option exercise. The sale amount is modest relative to typical director holdings. Monitor for any subsequent Form 4 filings to confirm execution and for any pattern of insider selling.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$105.35
T+0 close · Nov 12, 2026 · via day close
Latest settled
−5.80%
T+1 · $99.24
Vs SPY
−3.89%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $105.35entry
  2. T+1 · 19h ago −5.80%α −3.89% · $99.24
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Kristine Ball filed a Form 144 notice of intent to sell 18,000 shares of Oruka Therapeutics common stock, with an estimated aggregate market value of approximately $1.93 million. The shares were acquired via stock option exercise on the same date. The sale represents a modest portion of the director's holdings and is not unusual for a director-level insider.

Key Facts

  • Kristine Ball, a director, filed Form 144 to sell 18,000 shares of common stock.
  • Estimated aggregate market value of the proposed sale is $1,929,060.
  • Shares were acquired on 11/12/2026 via exercise of stock options from the issuer.
  • The proposed sale date is 11/12/2026, the same day as the filing.
  • The sale is to be executed through Morgan Stanley Smith Barney LLC.

Financial Impact

18,000 shares at approximately $107.17 per share, totaling about $1.93 million.

dilution

Risk Factors

  • Insider selling, even if routine, can signal reduced conviction if it becomes a pattern.
  • Form 144 is an intent to sell; the actual sale may not occur.

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-011029
Document: 0001950047-26-011029-index.html0001950047-26-011029
Document: 0001950047-26-011029.txt0001950047-26-011029

Track record

40 reports on ORKA

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
  3. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
  4. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
  5. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  6. Nov 12, 20264d ago 144 Neutral 2/10 Viewing Entry $105.35 Now $99.24 −5.80% settles Dec 14
  7. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
  8. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  9. Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  10. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
Showing 10 of 40

US Market Status

Market Closed · Opens in 7h 56m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026